Casgevy and Lyfgenia at a Glance
For 50 years, the only curative option for sickle cell disease was a bone marrow transplant from a matched sibling, which most patients did not have access to. That changed on December 8, 2023, when the FDA approved two gene therapies on the same day. Casgevy (exagamglogene autotemcel, made by Vertex Pharmaceuticals and CRISPR Therapeutics) is the first CRISPR-based therapy ever approved by the FDA. Lyfgenia (lovotibeglogene autotemcel, developed by bluebird bio and now made by Genetix Biotherapeutics) uses a lentiviral vector to add a modified beta-globin gene. Both are one-time, autologous treatments, meaning your own stem cells are modified in a lab and then infused back into you. Casgevy is approved for patients age 2 and older (expanded from 12 and older in July 2026), and Lyfgenia for patients age 12 and older, with sickle cell disease and a history of vaso-occlusive crises (VOCs).
The two therapies share a lot. Both require months of preparation, including stem cell collection by apheresis and high-dose myeloablative chemotherapy with busulfan to clear out the existing bone marrow before the modified cells are infused. Both produced near-complete elimination of vaso-occlusive crises in their pivotal trials. Both are administered only at FDA-Authorized Treatment Centers. Where they differ is in the underlying biology. Casgevy edits a regulatory gene called BCL11A so that your body restarts production of fetal hemoglobin, which does not sickle. Lyfgenia adds a modified version of the beta-globin gene that produces an anti-sickling form of hemoglobin called HbAT87Q. Both approaches give you sickling-resistant red blood cells; they just get there through different routes.
How Casgevy Works: CRISPR Editing of BCL11A
Casgevy uses CRISPR/Cas9, the gene-editing system that won the 2020 Nobel Prize in Chemistry for Jennifer Doudna and Emmanuelle Charpentier, to make a single targeted cut in your stem cells. The cut is in a specific spot of a gene called BCL11A, which normally tells the body to switch off fetal hemoglobin production shortly after birth. By disabling that switch in your stem cells, the modified cells go back to producing fetal hemoglobin (HbF), the form of hemoglobin we all make in the womb.
Fetal hemoglobin does not sickle. Babies with sickle cell disease are protected from VOCs for the first several months of life because they are still producing HbF, and only become symptomatic as their fetal hemoglobin gets replaced by the sickling adult form. Casgevy turns that biological clock back on. The modified cells, once reinfused after conditioning chemotherapy, take up residence in your bone marrow and produce red blood cells with high HbF for the rest of your life.
In the pivotal CLIMB-SCD-121 trial published in the New England Journal of Medicine (Frangoul et al., 2024), 29 of 30 evaluable patients (97%) were free of severe vaso-occlusive crises for at least 12 consecutive months over a follow-up window of at least 16 months. The trial enrolled patients age 12 to 35 with at least 2 severe VOCs per year over the prior 2 years.
How Lyfgenia Works: Lentiviral Addition of Anti-Sickling Beta-Globin
Lyfgenia takes a different approach. Instead of editing an existing gene, it adds a new copy of the beta-globin gene with a specific anti-sickling modification (called the T87Q variant, which means the amino acid threonine at position 87 has been replaced by glutamine of the beta-globin chain). This modified beta-globin protein, called HbAT87Q, refuses to sickle even under the low-oxygen conditions that cause normal sickle hemoglobin to polymerize.
The new gene is delivered to your stem cells using a lentiviral vector, a modified and disabled virus that has been used in other approved gene therapies, including Zynteglo for transfusion-dependent beta thalassemia and Skysona for cerebral adrenoleukodystrophy (both also from bluebird bio). The vector inserts the new gene into the DNA of your stem cells, and after the modified cells are infused back, they produce HbAT87Q alongside whatever sickle hemoglobin (HbS) the patient still produces. Most patients end up with enough HbAT87Q that the sickling fraction drops below the threshold that causes VOCs.
In the pivotal HGB-206 trial published in the New England Journal of Medicine (Kanter et al., 2022), 28 of 32 evaluable patients in Group C (the optimized dosing cohort) achieved complete resolution of severe vaso-occlusive crises during the 6 to 18 months after infusion. The same patients went from a median of 3.5 severe VOCs per year before treatment to zero severe VOCs after treatment.
Side-by-Side: Casgevy vs. Lyfgenia
Mechanism of action
Casgevy edits BCL11A to turn fetal hemoglobin back on. Lyfgenia adds a modified beta-globin gene that produces anti-sickling HbAT87Q. Both result in red blood cells that resist sickling, through different biology. Whether one approach proves more durable, more effective, or safer over decades of follow-up is a question the field is still answering.
Efficacy in pivotal trials
Both achieved near-complete VOC elimination in their primary endpoints. Casgevy showed 29 of 31 evaluable patients (93.5%) free of severe VOCs for at least 12 consecutive months. Lyfgenia showed 28 of 32 evaluable patients in the optimized cohort achieved complete resolution of severe VOCs. The trials used slightly different definitions of severe VOC and slightly different patient populations, so a direct head-to-head efficacy comparison from pivotal data alone is imprecise. Most patients in both trials eliminated their VOCs, and a small fraction did not respond as completely.
Safety: the Lyfgenia boxed warning for hematologic malignancy
This is the most important difference between the two therapies. The FDA approved Lyfgenia with a boxed warning for hematologic malignancy. Several Lyfgenia-treated patients developed myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The proposed mechanism involves the lentiviral vector inserting near oncogenic regions of DNA in some patients. Casgevy does not currently carry a boxed warning. Whether this means Casgevy is meaningfully safer in the long term, or whether the malignancy risk has simply not yet emerged in the smaller population of Casgevy-treated patients, is a genuinely open question. Long-term follow-up data is still maturing for both products.
Cost and insurance coverage for sickle cell gene therapy
Casgevy is priced at $2.2 million in the U.S. Lyfgenia is priced at $3.1 million. The roughly $900,000 gap reflects different pricing strategies. Both manufacturers offer outcomes-based reimbursement programs to insurers, in which the manufacturer rebates a portion of the cost if the patient does not achieve specified VOC reduction. Total cost of treatment is much higher than the list price when you include the apheresis, conditioning chemotherapy, hospital stay, and post-treatment monitoring. Full episode-of-care costs are typically estimated in the $3 million to $4 million range.
Eligibility and treatment process
Casgevy is FDA-approved for patients age 2 and older, and Lyfgenia for patients age 12 and older, with sickle cell disease and a history of recurrent VOCs. Both require treatment at an Authorized Treatment Center (ATC). The ATC list is similar between the two therapies but not identical, and some centers are authorized for both, others for only one. Both require apheresis (collection of stem cells from your blood), then myeloablative conditioning with busulfan, then infusion of the modified cells. From the first eligibility evaluation to hospital discharge typically takes 6 to 12 months.
Cost and Insurance Coverage for Sickle Cell Gene Therapy
The list prices ($2.2 million for Casgevy, $3.1 million for Lyfgenia) are negotiating starting points, not the final amounts insurers actually pay. Most patients have all or part of the therapy covered by their insurance, but coverage varies dramatically. Medicare and most large commercial insurers have established coverage policies. Medicaid coverage is the bigger issue, and varies by state. CMS's Cell and Gene Therapy Access Model is a multi-state outcomes-based payment program designed specifically to help state Medicaid programs cover sickle cell gene therapies; participation by states has grown over 2024 and 2025.
Both manufacturers run support programs (Vertex Connects for Casgevy, Genetix CARES for Lyfgenia) with case managers who help with treatment logistics and may help with travel and lodging during the multi-week treatment stay for eligible patients; Genetix CARES also offers fertility preservation support. Patients enrolling on either therapy should expect to work with the manufacturer's case management team and a hospital social worker as part of the treatment process.
The biggest financial concern for many sickle cell patients is access disparity. Sickle cell disease in the U.S. predominantly affects Black Americans, and a meaningful share of the patient population is on Medicaid. State-level Medicaid coverage of one-time multi-million-dollar therapies has been uneven across 2024 and 2025. The Sickle Cell Disease Association of America (SCDAA) and the Sickle Cell Disease Foundation track state-by-state coverage and can help families understand what their state covers.
Side Effects and Safety: What the Boxed Warning Means
Both therapies share many of the same side effects related to the conditioning chemotherapy and the immune recovery period. The conditioning agent, busulfan, is a high-dose chemotherapy drug that causes hair loss, mouth sores (mucositis), nausea, infection risk during immune recovery, and infertility. These are not unique to gene therapy; they are inherited from the bone-marrow-transplant approach the gene therapies are built on.
Infertility
The conditioning chemotherapy used for both Casgevy and Lyfgenia almost always causes infertility. This is a major consideration for patients of reproductive age. Pre-treatment fertility preservation (egg banking, sperm banking, ovarian or testicular tissue cryopreservation in pediatric patients) is a standard part of the pre-treatment evaluation and should be discussed before the apheresis step. Insurance coverage of fertility preservation in this context is variable, and is often covered by manufacturer assistance programs when commercial insurance does not cover it.
The Lyfgenia boxed warning, in detail
Several patients treated with Lyfgenia have developed myeloid malignancies. The FDA's hypothesis is that the lentiviral vector may insert near oncogenic regions of DNA in some patients, contributing to malignant transformation. The boxed warning calls for close monitoring with complete blood counts at least every 6 months and integration site analysis at months 6 and 12, and as needed after that, and the label says this monitoring should be lifelong. Patients enrolling on Lyfgenia should understand they are accepting a small but real malignancy risk in exchange for VOC elimination. Casgevy does not currently carry this warning, but the longer-term picture for both products is still emerging through ongoing patient follow-up registries.
Other safety considerations
Both therapies require a long hospital stay (typically 4 to 6 weeks) and ongoing infection precautions during immune recovery. Some patients have had transient liver issues, fevers, and graft delays. Procedure-related deaths have been rare in both pivotal trials, though long-term follow-up is still accumulating and the conditioning chemotherapy itself carries known risks. The long-term safety picture for both products is still being characterized through real-world follow-up.
Eligibility and What to Expect During Treatment
FDA-Authorized Treatment Centers
Both Casgevy and Lyfgenia are administered only at Authorized Treatment Centers (ATCs) credentialed and trained by the manufacturers. The ATC list grows over time. Some centers are authorized for both therapies; some are authorized for only one. Geographic distribution is uneven, since most ATCs are at major academic medical centers in metropolitan areas, which creates a barrier for patients in rural areas. Travel to a regional ATC plus a multi-week stay during the procedure is part of the practical decision, and patient assistance programs typically cover travel and lodging costs.
The treatment timeline
From the first eligibility evaluation through hospital discharge, the process typically takes 6 to 12 months. The major steps are pre-treatment evaluation (eligibility assessment, baseline labs, fertility consultation), apheresis to collect stem cells (often spread over 2 to 4 days), manufacturing of the modified cells in a specialized facility (3 to 6 months), conditioning chemotherapy (about 1 week of busulfan), infusion of the modified cells, and a hospital stay during immune recovery (4 to 6 weeks). Full immune reconstitution and return to normal activities takes several more months. Patients are typically followed in long-term registries for at least 15 years.
Pre-treatment evaluation
Eligibility for either therapy is more than just having sickle cell disease and a VOC history. Patients are evaluated for organ damage that might make the conditioning chemotherapy unsafe, particularly heart, lung, and liver function. Patients with severe end-organ damage (such as advanced sickle cell nephropathy, significant pulmonary hypertension, or impaired cardiac function) may not be candidates. The pre-treatment evaluation usually takes 2 to 3 months and is an important screening step.
Real-World Outcomes Two Years After Approval
Both therapies launched commercially in early 2024. By mid-2026, several hundred patients have received commercial-stage gene therapy in the U.S. across both products. Real-world reports through patient registries and conference presentations have generally been consistent with pivotal trial outcomes. Most patients eliminate VOCs. The conditioning side effects are difficult but recoverable. A small number of complications have occurred, including graft delays, prolonged immune recovery, and the malignancy risk seen on Lyfgenia. The full picture of 5- and 10-year outcomes will not be available for several more years.
The clearest non-clinical pattern emerging from real-world rollout is access. Patients in states with strong Medicaid coverage of sickle cell gene therapy are getting treated. Patients in states with weaker coverage are facing longer delays or being told they are not eligible for coverage. Patient advocacy organizations have been actively pushing for more uniform federal-level coverage standards.
How to Decide Between Casgevy and Lyfgenia
This is a decision that should be made with a hematologist who treats sickle cell disease patients regularly, ideally one who is at an Authorized Treatment Center for one or both therapies. Several questions matter most when working through it.
Have you optimized supportive care first? Hydroxyurea, L-glutamine, crizanlizumab (where access is available), and chronic transfusion programs are first-line treatments. Gene therapy is generally reserved for patients with significant VOC burden despite optimized supportive care, not as a first treatment.
How significant is your VOC history? The pivotal trials enrolled patients with at least 2 severe VOCs per year for the prior 2 years, and the FDA labels reflect those eligibility criteria. Patients with milder disease may be evaluated differently for eligibility.
Do you have a matched sibling donor for an allogeneic bone marrow transplant? For some patients, that older curative option remains the most evidence-supported choice with the longest follow-up data, especially in pediatric patients. Allogeneic transplant carries the risk of graft-versus-host disease that gene therapy avoids. Donor availability often resolves the question.
Are you comfortable with the Lyfgenia boxed warning? This is a subjective question and reasonable patients land on different answers. Some patients accept the small malignancy risk for the convenience of a single-vector approach. Others prefer Casgevy specifically because it does not carry the warning, accepting that long-term safety is still maturing for both.
What does your insurance actually cover? Sometimes only one therapy is covered, or one has a clearer path to approval. That practical reality often resolves the choice.
What is the closest Authorized Treatment Center for each? If one ATC is 6 hours from home and the other is 30 minutes, that affects family logistics during the multi-week treatment and post-treatment follow-up.
One email when Sickle Cell Disease trials change or an FDA decision lands. No newsletter, no spam.
Frequently Asked Questions
Are Casgevy and Lyfgenia cures for sickle cell disease?
Casgevy and Lyfgenia are both considered functionally curative for the vaso-occlusive component of sickle cell disease in successfully treated patients. Successfully treated patients no longer experience VOCs and no longer require regular blood transfusions. They still carry the original sickle cell mutation in their germline cells, so technically the underlying genetic disease has not been cured at the inheritance level; the modified stem cells produce sickle-resistant red blood cells for life. For the lived experience of a patient, the effect is the closest thing to a cure that has been available outside of allogeneic bone marrow transplant from a matched donor.
Are Casgevy and Lyfgenia approved for children under 12?
Casgevy now is. On July 1, 2026, the FDA expanded its approval to patients aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia. It was studied in children as young as 5; use in children aged 2 to 4 is based on extending those trial results. Lyfgenia is still approved only for patients 12 and older. For younger children, other options include hydroxyurea, blood transfusions, supportive care, and (for those with a matched sibling donor) allogeneic bone marrow transplant.
Is bone marrow transplant from a matched sibling still the better option if I have a sibling donor?
Matched-sibling allogeneic bone marrow transplant remains the right choice for some sickle cell patients, particularly pediatric patients with available donors. The procedure has been performed in sickle cell disease for decades and carries long-term follow-up data that gene therapy is still building. Some hematologists still consider matched-sibling transplant the curative option with the strongest evidence base. The trade-off is that allogeneic transplant carries the risk of graft-versus-host disease (GVHD) that gene therapy avoids. The decision depends on donor availability, patient age, organ function, and personal priorities, and should be discussed with a hematologist familiar with both options.
How much do Casgevy or Lyfgenia really cost out of pocket?
Casgevy has a U.S. list price of $2.2 million and Lyfgenia $3.1 million, but most patients pay limited or no out-of-pocket cost when insurance covers the therapy. Patients with strong commercial insurance typically have low out-of-pocket costs for the therapy itself, though indirect costs (travel, lodging during the multi-week stay, lost income) can be substantial. Medicaid patients typically have no out-of-pocket cost for the therapy if it is covered by their state. Insurance denial of the therapy entirely is the bigger financial risk than co-pays. Both manufacturers offer patient assistance programs to help with travel, lodging, and ancillary costs not covered by insurance. The Sickle Cell Disease Association of America can connect patients with case workers familiar with current coverage patterns.
What is the Lyfgenia boxed warning, and how worried should I be?
The boxed warning is for hematologic malignancy. Several Lyfgenia-treated patients have developed myeloid malignancies, including acute myeloid leukemia. The proposed mechanism involves the lentiviral vector inserting near oncogenic regions of DNA. The risk is small but real, and the FDA recommends lifetime monitoring. Most hematologists frame the choice as: Lyfgenia eliminates your VOCs but adds a small malignancy risk you will need to monitor for life; Casgevy eliminates your VOCs without that specific known risk, though long-term safety is still maturing for both products. This is a real conversation to have with your hematologist, not a reason to dismiss Lyfgenia entirely.
Can I have children after Casgevy or Lyfgenia?
The conditioning chemotherapy used in both protocols (busulfan) almost always causes infertility. Fertility preservation (egg banking, sperm banking, or in pre-pubertal patients ovarian or testicular tissue cryopreservation) is a standard part of the pre-treatment evaluation and should be discussed before any cells are collected. Pregnancy after treatment using preserved gametes is possible. Some patients have unexpectedly retained fertility after the conditioning, but it cannot be relied upon, and patients of reproductive age should plan for fertility preservation as if conditioning will cause infertility.
What other sickle cell gene therapies are in development?
Several. Editas Medicine's reni-cel (formerly EDIT-301) is a CRISPR-edited therapy targeting the gamma-globin promoter to reactivate fetal hemoglobin. Beam Therapeutics' BEAM-101 uses base editing rather than standard CRISPR. Other lentiviral and gene-editing approaches are at earlier stages. The pipeline beyond Casgevy and Lyfgenia is expected to mature over the next several years, and some next-generation programs may have safety advantages over current options.
What happened to Oxbryta (voxelotor)?
Pfizer voluntarily withdrew Oxbryta from global markets in September 2024 after post-marketing safety data showed an unfavorable mortality and complication signal. Patients on Oxbryta at the time of withdrawal needed alternative supportive care, typically hydroxyurea optimization, transfusion programs, or evaluation for gene therapy. The Oxbryta withdrawal is unrelated to Casgevy and Lyfgenia, but it removed one option from the broader sickle cell treatment menu and shifted some patients toward considering gene therapy who might not otherwise have.
Where can I find a clinical trial for sickle cell disease?
Trial Friend's sickle cell disease page lists currently enrolling studies pulled from ClinicalTrials.gov. The Sickle Cell Disease Association of America (SCDAA), the Cure Sickle Cell Initiative at NHLBI, and individual Authorized Treatment Centers also maintain trial information. Trial enrollment for next-generation gene therapies, base editing approaches, and improved supportive therapies is active and growing.